Acute Exacerbation of COPD (AECOPD)
Sustained worsening of dyspnea, cough, or sputum beyond normal day-to-day variation. NIV before intubation. Bronchodilators + steroids are the backbone. Find and treat the trigger. For chronic / outpatient COPD management (GOLD staging, ABE classification, inhaler step-up, biologics), see COPD Chronic Management.
↪
Also see: COPD Chronic Management (GOLD 2026) for outpatient staging, ABE classification, inhaler step-up, and biologic candidacy.
🔍 Overview
What changed in GOLD 2026 (acute-care relevant points): (1) Pulmonary rehab within 4 weeks post-exacerbation strongly emphasized, reduces 1-year mortality and rehospitalization, plan it before discharge. (2) Biologics for severe eosinophilic COPD (mepolizumab, benralizumab, dupilumab) if blood eos ≥ 300 + frequent exacerbations on triple therapy, refer to outpatient pulm at discharge. (3) ICS without LABA is not appropriate, if you're discharging on inhaled steroid, pair it with LABA. Full GOLD 2026 changes (chronic).
Definition
AECOPD is a sustained worsening of respiratory symptoms -increased dyspnea, cough frequency, and/or sputum production (volume, purulence) -beyond normal day-to-day variation, requiring a change in therapy. Anthonisen 1987
This is the most common cause of COPD-related morbidity and mortality. Frequent exacerbators (≥ 2 per year) have accelerated lung function decline and reduced survival. ICU mortality ranges from 10–30%.
This is the most common cause of COPD-related morbidity and mortality. Frequent exacerbators (≥ 2 per year) have accelerated lung function decline and reduced survival. ICU mortality ranges from 10–30%.
Severity Classification: Mild (bronchodilators only) | Moderate (requires antibiotics ± steroids) | Severe (hospitalization) | Very Severe (ICU admission)
Pathophysiology -Why COPD Patients Crash
The core problem is dynamic hyperinflation:
Trigger (infection, irritant) → airway inflammation → mucus plugging + bronchospasm → prolonged expiratory time → incomplete exhalation → air trapping → progressive hyperinflation → flattened diaphragm → reduced inspiratory capacity → respiratory muscle fatigue → hypercapnic respiratory failure.
Air stacking creates intrinsic PEEP (auto-PEEP), forcing patients to breathe against their own trapped air. This is why you see tripod positioning, pursed-lip breathing, and accessory muscle recruitment -they're desperately trying to empty their lungs before the next breath.
Trigger (infection, irritant) → airway inflammation → mucus plugging + bronchospasm → prolonged expiratory time → incomplete exhalation → air trapping → progressive hyperinflation → flattened diaphragm → reduced inspiratory capacity → respiratory muscle fatigue → hypercapnic respiratory failure.
Air stacking creates intrinsic PEEP (auto-PEEP), forcing patients to breathe against their own trapped air. This is why you see tripod positioning, pursed-lip breathing, and accessory muscle recruitment -they're desperately trying to empty their lungs before the next breath.
Common Precipitants of AECOPD
Work through this list in every admission, and note the right-hand column: some of these precipitate a true exacerbation, while others ARE the diagnosis instead of it. That distinction changes what you treat. The six alternative diagnoses are set out as the 6 P's in the next section.
| # | Cause | Details | Precipitant, or the diagnosis itself? |
|---|---|---|---|
| 1 | Pneumonia / Pulmonary infection | Most common trigger. Viral ~50% (rhinovirus, influenza, RSV, parainfluenza). Bacterial ~30% (H. influenzae, S. pneumoniae, M. catarrhalis). | Both. An airway infection precipitates a true exacerbation, but an infiltrate on imaging means pneumonia rather than AECOPD |
| 2 | Pulmonary embolism | ~12% prevalence across hospitalized AECOPD overall; ~16% in unexplained AECOPD (Aleva meta-analysis 2017). Often missed. Always consider if no clear infectious trigger, pleuritic pain, unexplained tachycardia, or hypoxia out of proportion. | The diagnosis itself. A PE does not set off an exacerbation, it explains the breathlessness |
| 3 | Pneumothorax | Especially in emphysematous patients with bullae. CXR mandatory on all AECOPD admissions. | The diagnosis itself |
| 4 | Pleural effusion | Can worsen dyspnea and restrict lung expansion. Rule out on CXR. | The diagnosis itself |
| 5 | Poor compliance | Missed inhalers (LAMA/LABA/ICS non-adherence) -very common and modifiable. Always ask about medication use. | Precipitant |
| 6 | Pollution / environmental | PM2.5, ozone spikes, cold air, biomass fuel smoke, occupational dust. Leading cause of COPD in low-income countries (biomass > smoking). Both a cause of COPD development and a trigger for exacerbations. | Precipitant |
Don't Miss PE: PE occurs in ~12% of AECOPD hospitalizations overall (~16% in unexplained AECOPD) per Aleva meta-analysis 2017. Consider CTPA if: no clear infectious trigger, pleuritic pain, unexplained tachycardia, or hypoxia out of proportion to exam findings.
Also consider: temperature extremes, and drugs (below). Heart failure, ACS or arrhythmia, and mucus plugging or aspiration are covered as Pump, Pulse and Plug in the 6 P's below, since each is an alternative diagnosis rather than a precipitant.
Common Mistake: Non-selective beta-blockers (propranolol, carvedilol), sedatives/opioids, and ACE inhibitors can trigger or worsen AECOPD. Always review the med list -ACE-inhibitor cough is frequently misdiagnosed as an exacerbation.
The 6 P's -Mimics of AECOPD
This is the 6 P's on this page. They are the alternative diagnoses, meaning what else could be causing the breathlessness, and they are deliberately kept separate from the precipitants listed above. Pneumonia, PE and pneumothorax appear in both places, because an airway infection can precipitate a true exacerbation while an infiltrate, clot or air leak is the diagnosis instead of it. Either way you have to go looking.
The reasoning is inherently subtractive: dyspnea + known COPD + nothing else explains it = exacerbation. AECOPD is a diagnosis of exclusion, so these are the six you must clear.
| # | P | Suspect it when | Why it matters |
|---|---|---|---|
| 1 | PE | No infectious prodrome, pleuritic pain, hypoxemia out of proportion to the wheeze, or poor response to bronchodilators | The highest-yield miss. Roughly 1 in 6 hospitalized patients with an unexplained exacerbation (pooled 16.1%), and 68% of those emboli were main, lobar or interlobar, so it is not subsegmental noise. Aleva, Chest 2017 |
| 2 | Pneumonia | Fever, focal consolidation, higher CRP | An infiltrate makes it pneumonia with COPD, not AECOPD: different antibiotic duration, different steroid logic, higher mortality |
| 3 | Pneumothorax | Sudden pain, unilateral signs, sudden deterioration on NIV | Bullous disease makes it disproportionately common and easy to miss on a portable film. Look before applying positive pressure, which can convert it to tension |
| 4 | Pump failure | Orthopnea, elevated JVP, edema, raised BNP | COPD and HFpEF overlap heavily in the same smoker. BNP is blunted by obesity and raised by cor pulmonale, so it helps but does not settle it. Diurese rather than escalate bronchodilators |
| 5 | Pulse | Irregular pulse, tachycardia that will not settle, chest pain or ischemic ECG change | ACS or a new arrhythmia (AF, atrial tachycardia, MAT). Demand ischemia and tachyarrhythmia both present as "I cannot breathe", and beta-agonists aggravate the arrhythmias |
| 6 | Plug / aspiration | Abrupt onset, lobar collapse, asymmetric air entry, or a choking or reduced-consciousness event | Mucus plugging, foreign body, aspiration or an upper airway process. The problem is the airway itself rather than the small airways, so bronchodilators will not fix it |
Clinical Presentation
Cardinal symptoms (Anthonisen criteria):
- Increased dyspnea -most sensitive symptom
- Increased sputum volume
- Increased sputum purulence -green/yellow suggests bacterial infection
Physical exam findings:
- Accessory muscle use (sternocleidomastoid, scalenes), tripod positioning
- Pursed-lip breathing (creates back-pressure to prevent airway collapse)
- Prolonged expiratory phase, diffuse expiratory wheezing
- Tachypnea (RR > 24), tachycardia, diaphoresis
- Cyanosis, asterixis (CO₂ retention), altered mental status
ICU Admission Criteria
- Severe dyspnea unresponsive to initial therapy (continued accessory muscle use, unable to speak in sentences)
- Altered mental status -confusion, somnolence, or coma
- Persistent hypoxemia: SpO₂ < 88% despite FiO₂ ≥ 0.4
- Severe or worsening respiratory acidosis: pH < 7.25 or PaCO₂ > 70 mmHg
- Acidosis not improving with NIV (recheck ABG at 1–2 hours)
- Hemodynamic instability requiring vasopressors
- NIV intolerance or failure
Key Point: A rising PaCO₂ with falling pH despite maximal therapy is an indication for intubation. Don't wait for respiratory arrest.
🧪 Workup & Diagnosis
Immediate Assessment
- ABG -mandatory in moderate-severe AECOPD. Assess pH, PaCO₂, PaO₂. Do NOT rely on SpO₂ alone.
- CXR -exclude pneumonia, pneumothorax, pulmonary edema, pleural effusion
- ECG -P pulmonale, right heart strain, arrhythmias (AF common in COPD)
- CBC -leukocytosis (infection), polycythemia (chronic hypoxia)
- BMP -metabolic alkalosis (chronic CO₂ retainer), hypokalemia (β₂ agonists)
- BNP / NT-proBNP -exclude heart failure as trigger or co-contributor
- Troponin if cardiac involvement suspected
ABG Interpretation in AECOPD
| Pattern | pH | PaCO₂ | HCO₃ | Interpretation |
|---|---|---|---|---|
| Acute hypercapnia | < 7.35 | > 45 | Normal / mildly ↑ | Acute exacerbation -treat aggressively |
| Chronic compensated | 7.35–7.45 | > 45 | ↑↑ (≥ 30) | Stable CO₂ retainer -know their baseline |
| Acute-on-chronic | < 7.35 | > 45 (above baseline) | ↑↑ | Most common pattern -compensated chronically + acute decompensation |
| pH < 7.25 | < 7.25 | > 60 | ↑ | Severe -NIV now, low threshold for intubation |
CO₂ Retainer Pearl: Chronic CO₂ retainers have high HCO₃ as compensation. A "normal" PaCO₂ of 45 mmHg may represent acute decompensation in someone whose baseline is 60 mmHg. Always compare to prior ABG or clinic notes.
Sputum & Microbiology
- Sputum Gram stain + culture if purulent sputum and no recent culture data
- Respiratory viral panel (if influenza season -guides oseltamivir)
- Legionella urine antigen + Pneumococcal urine antigen if severe / ICU
- Procalcitonin -helps distinguish bacterial vs viral trigger PRORATA 2010
- Consider CTPA if PE not excluded (atypical presentation, no clear infectious trigger)
Spirometry -Don't Do It Acutely
Do NOT perform spirometry during an acute exacerbation. Results are unreliable, the maneuver is uncomfortable, and it can worsen respiratory distress. Review prior PFTs in the chart for baseline FEV₁ context.
For chronic COPD baseline classification (GOLD Stage 1-4 by FEV₁ % predicted, GOLD ABE groups by symptoms + exacerbation history, inhaler step-up, biologics for eosinophilic phenotype), see the COPD Chronic Management topic. The acute exacerbation workflow below focuses on managing THIS event -not setting outpatient maintenance therapy.
🚨 Management
Don't Confuse the Protocol with Acute Asthma
⚠️ Same drugs, different protocol. Treating an AECOPD patient like an asthmatic (q20 min × 3 albuterol + 100% O₂) induces hypercapnia and hypoxic-drive crash. The first three decisions diverge:
| Decision | AECOPD | Acute asthma |
|---|---|---|
| Albuterol frequency | q1–4 h scheduled, no q20 min loading | q20 min × 3 in first hour, front-loaded |
| Continuous nebs | Rarely, intermittent works; chronic patients don't tolerate continuous | Yes for severe (10–15 mg/hr) |
| Ipratropium duration | Continued throughout admission (often DuoNeb q4–6 h) | First 3 nebs only (ceiling effect, Rodrigo 2005) |
| O₂ target | 88–92% (controlled O₂, avoid hypercapnic respiratory failure) AVOID, 2010 | 93–95% |
| Steroids | Prednisone 40 mg × 5 d REDUCE, 2013 | Prednisone 40–60 mg × 5 d |
| Antibiotics | YES if Anthonisen ≥ 2 of 3 (↑ dyspnea, sputum volume, sputum purulence) | Usually NO |
| NIV | First-line for hypercapnic exacerbation (strong evidence, > 80% avoid intubation) | Bridge only, low threshold to intubate |
| IV magnesium | Not standard, weak evidence | 2 g IV for severe (3Mg) |
| Decompensation tempo | Days | Hours |
What's the same: dose per neb (albuterol 2.5–5 mg, ipratropium 0.5 mg), DuoNeb formulation, steroid burst with no taper if ≤ 5 days, sit upright. Full asthma acute protocol →
Management Algorithm
Immediately -Controlled Oxygen
Target SpO₂ 88–92% -and equally important: do NOT exceed 92% in known or suspected CO₂ retainers. Austin 2010
Why the upper limit matters:
Why the upper limit matters:
- Haldane effect -Dominant mechanism (~70%). Oxygenated Hb offloads CO₂ into plasma → PaCO₂ rises independent of respiratory rate.
- V/Q mismatch -High FiO₂ abolishes hypoxic pulmonary vasoconstriction → blood flows to poorly-ventilated units → worsened dead space.
- Hypoxic drive suppression -Correcting hypoxia reduces peripheral chemoreceptor drive → hypoventilation (real but overemphasized).
Common Error: Placing COPD patient on 15L NRB → arrives with PaCO₂ 90, pH 7.15. SpO₂ 100% is not reassuring in COPD -it may be the problem.
Bronchodilators -First-Line Treatment
Short-acting β₂ agonist (SABA) + short-acting muscarinic antagonist (SAMA) via nebulizer.
Albuterol (Ventolin) 2.5–5 mg + ipratropium (Atrovent) 0.5 mg neb q1h × 1–2 if severe, then scheduled q4–6h (or DuoNeb [albuterol + ipratropium pre-mix] combination, same schedule). Do NOT use the asthma q20 min × 3 loading regimen, AECOPD doesn't need it and chronic patients tolerate intermittent dosing better.
Continue ipratropium throughout admission (unlike asthma where it's stopped after 3 doses).
MDI + spacer equally effective as nebulizer in mild-moderate exacerbations (and doesn't aerosolize virus). Turner, 1997
Continuous albuterol nebulizer only if severe bronchospasm not responding to intermittent dosing (less commonly needed in COPD than asthma).
Albuterol (Ventolin) 2.5–5 mg + ipratropium (Atrovent) 0.5 mg neb q1h × 1–2 if severe, then scheduled q4–6h (or DuoNeb [albuterol + ipratropium pre-mix] combination, same schedule). Do NOT use the asthma q20 min × 3 loading regimen, AECOPD doesn't need it and chronic patients tolerate intermittent dosing better.
Continue ipratropium throughout admission (unlike asthma where it's stopped after 3 doses).
MDI + spacer equally effective as nebulizer in mild-moderate exacerbations (and doesn't aerosolize virus). Turner, 1997
Continuous albuterol nebulizer only if severe bronchospasm not responding to intermittent dosing (less commonly needed in COPD than asthma).
Systemic Corticosteroids
Prednisolone 40 mg PO daily × 5 days -reduces treatment failure and length of stay. REDUCE, 2013 showed 5 days non-inferior to 14 days.
Use IV methylprednisolone 60 mg daily if unable to take PO (NPO, vomiting) -equivalent to prednisone 40 mg PO, same 5-day course, no taper. Do NOT use 125 mg q6h (asthma-style dosing, not GOLD-aligned for AECOPD; lower-dose corticosteroids < 80 mg prednisone-equivalent are non-inferior).
No taper needed for 5-day course. Taper only if > 3 weeks of steroids.
Use IV methylprednisolone 60 mg daily if unable to take PO (NPO, vomiting) -equivalent to prednisone 40 mg PO, same 5-day course, no taper. Do NOT use 125 mg q6h (asthma-style dosing, not GOLD-aligned for AECOPD; lower-dose corticosteroids < 80 mg prednisone-equivalent are non-inferior).
No taper needed for 5-day course. Taper only if > 3 weeks of steroids.
🔄 Updated Practice: Old teaching: 10-14 day steroid course for COPD exacerbation. REDUCE 2013 showed 5 days of prednisone 40mg is non-inferior to 14 days. Shorter course = less hyperglycemia, less immunosuppression, same outcomes. Also: old teaching was to check theophylline levels and use IV aminophylline -this is rarely done anymore due to narrow therapeutic index and better alternatives.
Antibiotics (if indicated)
Antibiotics reduce treatment failure in moderate-severe AECOPD with purulent sputum. Anthonisen 1987
Anthonisen Criteria (all 3 = definitely treat; 2/3 = probably treat; 1/3 = no benefit):
① Increased dyspnea ② Increased sputum volume ③ Increased sputum purulence
Empiric choice: Amoxicillin-clavulanate 875/125 mg PO BID OR doxycycline 100 mg BID × 5–7 days. Levofloxacin if Pseudomonas risk (structural lung disease, frequent hospitalization, recent abx).
Anthonisen Criteria (all 3 = definitely treat; 2/3 = probably treat; 1/3 = no benefit):
① Increased dyspnea ② Increased sputum volume ③ Increased sputum purulence
Empiric choice: Amoxicillin-clavulanate 875/125 mg PO BID OR doxycycline 100 mg BID × 5–7 days. Levofloxacin if Pseudomonas risk (structural lung disease, frequent hospitalization, recent abx).
Non-Invasive Ventilation (NIV / BiPAP) -Before Intubation
Start NIV early in hypercapnic respiratory failure (pH < 7.35 + PaCO₂ > 45). Reduces intubation rates, ICU mortality, and length of stay. Brochard 1995; Plant 2000
Initial settings: IPAP 12–16 cmH₂O, EPAP 4–5 cmH₂O. Titrate IPAP for patient comfort + TV 6–8 mL/kg. Add supplemental O₂ to maintain SpO₂ 88–92%.
NIV Contraindications: Reduced consciousness, inability to protect airway, vomiting, facial trauma/burns, hemodynamic instability, copious secretions, pH < 7.15 with poor trajectory.
Initial settings: IPAP 12–16 cmH₂O, EPAP 4–5 cmH₂O. Titrate IPAP for patient comfort + TV 6–8 mL/kg. Add supplemental O₂ to maintain SpO₂ 88–92%.
NIV Contraindications: Reduced consciousness, inability to protect airway, vomiting, facial trauma/burns, hemodynamic instability, copious secretions, pH < 7.15 with poor trajectory.
Intubation -When NIV Fails or Contraindicated
RSI with cautious ventilator settings to avoid auto-PEEP.
Initial vent: TV 6–8 mL/kg PBW, RR 10–12/min (lower than ARDS!), I:E 1:3 or 1:4, PEEP 5 cmH₂O.
Low RR = more time for exhalation = less air trapping.
If hemodynamic collapse after intubation → disconnect ETT → manual exhalation (auto-PEEP release).
Check plateau pressure + perform expiratory hold for intrinsic PEEP measurement.
Initial vent: TV 6–8 mL/kg PBW, RR 10–12/min (lower than ARDS!), I:E 1:3 or 1:4, PEEP 5 cmH₂O.
Low RR = more time for exhalation = less air trapping.
If hemodynamic collapse after intubation → disconnect ETT → manual exhalation (auto-PEEP release).
Check plateau pressure + perform expiratory hold for intrinsic PEEP measurement.
NIV Success vs Failure
| Parameter | Good Response (1–2h) | NIV Failure → Intubate |
|---|---|---|
| pH | Improving toward 7.35 | pH < 7.25 or worsening |
| PaCO₂ | Decreasing | Rising despite NIV |
| RR | Decreasing | Still > 30 after 1–2h |
| HR | Decreasing | Worsening tachycardia |
| Mentation | More alert, cooperative | Worsening confusion, agitation |
| Accessory muscles | Decreasing | Unchanged or increasing |
Discharge Criteria & Optimization
- Able to use inhalers correctly
- Needs bronchodilators no more frequent than q4h
- On room air or at baseline O₂ requirement
- Able to eat and sleep without significant dyspnea
- Clinically and hemodynamically stable for 12–24h
- Maintenance therapy optimized (LAMA + LABA ± ICS reviewed and prescribed)
- Smoking cessation counseling
- Pulmonary rehab referral
- Follow-up within 1–4 weeks
Swipe for more examples
📋 Case 1, Standard AECOPD Management
Patient: 68M with severe COPD (FEV1 35%), presents with worsening dyspnea × 3 days, productive cough with purulent sputum, RR 28, SpO₂ 86% on RA.
Immediate: O₂ via nasal cannula → target SpO₂ 88–92% (NOT 100% -risk of CO₂ retention in COPD). Start BiPAP if not improving (IPAP 12, EPAP 5).
Bronchodilators: Albuterol (ProAir) 2.5mg + ipratropium (Atrovent) 0.5mg nebs q20min × 3, then q4h.
Steroids: Prednisone (Deltasone) 40mg PO daily × 5 days (REDUCE trial -5 days = 14 days in outcomes).
Antibiotics: Azithromycin (Zithromax) 500mg PO daily × 3 days (indicated because purulent sputum -meets ≥ 2 of 3 Anthonisen criteria: ↑ dyspnea, ↑ sputum volume, ↑ sputum purulence).
ABG: pH 7.31, PaCO₂ 58, PaO₂ 62 → acute-on-chronic respiratory acidosis. BiPAP initiated. Repeat ABG in 1–2h.
Key: If BiPAP fails (worsening acidosis, inability to protect airway, AMS) → intubate. But BiPAP prevents intubation in ~75% of COPD exacerbations.
📋 Case 2, AECOPD Requiring Intubation
Patient: 74F with very severe COPD (FEV1 22%), brought in by EMS obtunded. RR 8, SpO₂ 78%, GCS 8. ABG: pH 7.12, PaCO₂ 95, PaO₂ 48.
This patient is too sick for BiPAP. Altered mental status + inability to protect airway = intubate.
Intubation strategy:
- Pre-oxygenate with BVM at low rate, avoid breath-stacking in COPD.
- RSI: Ketamine 1.5 mg/kg (bronchodilator properties, maintains hemodynamics) + rocuronium 1.2 mg/kg.
- Ventilator settings: Low RR (10–12), TV 6–8 mL/kg PBW, long expiratory time (I:E ratio 1:4 or 1:5) to prevent auto-PEEP/breath-stacking.
- Watch for auto-PEEP: If hypotension post-intubation → disconnect from vent for 10 seconds (releases trapped air). Most common cause of post-intubation hypotension in COPD.
Ongoing: Nebs via vent circuit. IV steroids (methylprednisolone 60 mg IV daily = prednisone 40 mg PO equivalent; transition to PO when able, 5-day total course, no taper). Antibiotics. Daily SBT when improving.
Key lesson: COPD + intubation = low rate, long expiratory time, watch for auto-PEEP. Post-intubation hypotension → disconnect and let air out before reaching for pressors.
📋 Case 3, AECOPD vs Pneumonia vs PE Overlap
Patient: 70M with moderate COPD, presents with dyspnea × 2 days, low-grade fever 38.2°C, HR 108, SpO₂ 89%. Treated as AECOPD with steroids, nebs, azithromycin. Not improving at 48h.
Re-evaluation:
- CXR: Right lower lobe infiltrate → pneumonia, not just AECOPD. Need broader antibiotics.
- D-dimer: 1,850 (elevated). Given immobility + tachycardia out of proportion → CTPA ordered → subsegmental PE found.
- Procalcitonin: 0.8 → supports bacterial infection. Confirms need for antibiotics.
Revised treatment:
- Upgrade antibiotics: Ceftriaxone 1g IV daily + azithromycin 500mg IV daily (CAP coverage).
- Anticoagulation for PE: Heparin drip → transition to apixaban once stable.
- Continue: Steroids, bronchodilators, O₂ targeting 88–92%.
Key lesson: When AECOPD doesn't improve in 48h → think beyond COPD. Get a CXR (pneumonia?), consider PE (especially if tachycardia out of proportion), and check procalcitonin. COPD patients often have overlapping diagnoses.
📋 Case 4, AECOPD with Pneumothorax
Patient: 62M with emphysema, sudden onset of severe dyspnea and pleuritic chest pain. SpO₂ 82%. Absent breath sounds on the right. Trachea midline.
CXR: Large right-sided pneumothorax (~40%). No mediastinal shift (simple pneumothorax, not tension, yet).
Why this matters in COPD:
- COPD patients have minimal pulmonary reserve, even a small PTX can be life-threatening.
- Bullous emphysema predisposes to spontaneous pneumothorax.
- BiPAP/CPAP is CONTRAINDICATED with pneumothorax, positive pressure worsens it → tension PTX.
Treatment:
- Chest tube (28-32Fr), large PTX in symptomatic COPD patient requires drainage, not observation.
- High-flow O₂ (if no CO₂ retention risk) accelerates pleural air reabsorption.
- Do NOT start BiPAP until tube is in place and lung is re-expanded.
- If recurrent → pleurodesis (chemical or surgical) or VATS referral.
- Treat underlying AECOPD concurrently (steroids, nebs, antibiotics if indicated).
Key lesson: Sudden worsening in COPD + absent breath sounds = get a CXR NOW. Rule out pneumothorax before slapping on BiPAP, positive pressure + PTX = tension physiology = cardiac arrest.
📋 Case 5, Frequent Exacerbator: Discharge Planning
Patient: 66F with COPD, 4th hospitalization for AECOPD in the past year. Currently stable on room air, ready for discharge. This is a frequent exacerbator phenotype, high risk of readmission and mortality.
Before discharge, optimization checklist:
- Inhaler technique: Watch the patient use their inhalers. Up to 90% use them incorrectly. Teach, re-teach, and verify.
- Triple therapy: ICS/LABA/LAMA (e.g., Trelegy Ellipta), reduces exacerbations by ~25% vs dual therapy. Consider if eosinophils ≥ 300.
- Azithromycin prophylaxis: 250mg daily or 500mg 3×/week, reduces exacerbation frequency by ~27%. Check ECG (QTc) and hearing before starting. Avoid in NTM risk patients.
- Pulmonary rehab referral: Single most impactful intervention for reducing readmissions. Start within 4 weeks of discharge.
- Smoking cessation: If still smoking, varenicline (Chantix) + counseling. Only intervention that changes disease trajectory.
- Vaccinations: Influenza (annually), pneumococcal (PCV20), COVID, RSV (if ≥ 60).
- Home O₂: If resting SpO₂ ≤ 88% or PaO₂ ≤ 55 on stable state, refer for home O₂ (improves mortality in hypoxemic COPD).
- Action plan: Written instructions for when to start prednisone burst + antibiotics at home vs call vs go to ED.
Key lesson: The real COPD management happens at discharge, not during the admission. Optimize inhalers, start prophylactic azithromycin, refer to pulm rehab, and give a written action plan. This prevents the next admission.
💊 Medications & Doses
Bronchodilators
| Drug | Class | Dose (Acute) | Notes |
|---|---|---|---|
| Albuterol (Ventolin, ProAir) | SABA | 2.5–5 mg neb q1h × 1–2 if severe, then q4–6h scheduled. Continuous 10–15 mg/hr only for refractory bronchospasm. | First-line. Watch hypokalemia and β₂-driven lactic acidosis with frequent dosing. Do NOT use the asthma q20 min × 3 protocol. |
| Ipratropium (Atrovent) | SAMA | 0.5 mg neb q4–6h, continued throughout admission | Combine with albuterol, additive bronchodilation. Less tachycardia. Unlike asthma, ipratropium has sustained benefit in COPD (don't stop after 3 doses). |
| Albuterol + Ipratropium (DuoNeb) | SABA+SAMA | 2.5/0.5 mg neb q1h × 1–2 if severe, then q4–6h scheduled | Single-vial combination, preferred in acute setting for convenience. Same schedule as separate components. |
| Magnesium sulfate | Smooth muscle relaxant | 1.2–2g IV over 20 min | Consider in severe/refractory bronchospasm -evidence mainly from asthma but used in COPD |
Corticosteroids
| Drug | Dose | Duration | Evidence |
|---|---|---|---|
| Prednisolone (Orapred) | 40 mg PO daily | 5 days REDUCE, 2013 | Non-inferior to 14 days; reduces treatment failure and LOS |
| Methylprednisolone (Solu-Medrol) | 60 mg IV daily (equivalent to prednisone 40 mg PO) | 5 days, switch to PO when able. No taper. | Use only if NPO / unable to absorb PO. Avoid 125 mg q6h -asthma-style dosing, not GOLD-aligned for AECOPD. Lower-dose corticosteroids (< 80 mg prednisone-equivalent) non-inferior to higher doses. |
| Dexamethasone (Decadron) | 6 mg IV/PO daily (= prednisone 40 mg equivalent) | 5 days, no taper | Alternative; longer half-life, once-daily dosing. Avoid 8 mg -that is ~53 mg prednisone-equivalent, exceeds the GOLD-recommended 40 mg-equivalent target. |
Antibiotics
| Drug | Dose | Indication | Notes |
|---|---|---|---|
| Amoxicillin-clavulanate | 875/125 mg PO BID × 5–7d | First-line moderate AECOPD with purulent sputum | Covers H. influenzae, S. pneumo, M. catarrhalis |
| Doxycycline (Vibramycin) | 100 mg PO BID × 5–7d | Alternative to amox-clav | Good atypical coverage; useful if penicillin allergy |
| Azithromycin (Zithromax) | 500 mg PO × 1, then 250 mg daily × 4d | Atypical coverage, macrolide option | Resistance rates rising; QTc monitoring |
| Levofloxacin (Levaquin) | 500–750 mg PO/IV daily × 5–7d | Pseudomonas risk, structural lung disease, frequent hospitalizations | QTc prolongation; Achilles tendon rupture risk; reserve for high-resistance risk |
| Piperacillin-tazobactam (Zosyn) | 3.375g q6h IV | ICU-level AECOPD with Pseudomonas risk | Bronchiectasis, structural lung disease, prior Pseudomonas isolation |
Procalcitonin-Guided Antibiotics: PCT < 0.1 = unlikely bacterial → withhold antibiotics. PCT 0.1–0.25 = equivocal. PCT > 0.25 = bacterial → treat. Reduces antibiotic prescription without affecting clinical outcomes. ProHOSP, 2009 (PRORATA 2010 was an ICU sepsis trial -separate evidence base, do not conflate.)
Maintenance Therapy -Initiate Before Discharge
| Drug Class | Example | Notes |
|---|---|---|
| LAMA (Long-acting muscarinic antagonist) | Tiotropium (Spiriva) 18 mcg daily | Reduces exacerbation frequency. Most important maintenance drug. UPLIFT, 2008 |
| LABA (Long-acting β₂ agonist) | Salmeterol or Formoterol | Add to LAMA in moderate-severe disease |
| ICS + LABA | Budesonide/Formoterol | Add ICS if ≥ 2 exacerbations/year or eosinophils ≥ 300. IMPACT, 2018 -triple therapy reduces exacerbations |
| Roflumilast | 500 mcg PO daily | PDE4 inhibitor. Add in severe COPD (FEV₁ < 50%, chronic bronchitis, frequent exacerbations). GI side effects common. |
| Azithromycin prophylaxis | 250 mg 3×/week or 500 mg daily | Reduces exacerbation frequency in former/non-smokers. Albert 2011. Monitor QTc + hearing. |
📋 On Rounds
On Rounds
Pimp Questions
Why do we target SpO₂ 88–92% in COPD and not 94–98%?
Three mechanisms, ranked by contribution: (1) Haldane effect (dominant, ~70%) -deoxyHb binds CO₂ ~3.5× more efficiently than oxyHb. Fully saturating Hb with O₂ offloads CO₂ into plasma → PaCO₂ rises even without any change in breathing. (2) V/Q mismatch worsening -high FiO₂ abolishes hypoxic pulmonary vasoconstriction → blood floods poorly-ventilated alveoli → dead space increases → CO₂ retention
What is auto-PEEP and how does it affect management in intubated COPD?
Auto-PEEP (intrinsic PEEP) occurs when air trapping prevents complete exhalation before the next breath is delivered. Gas accumulates → lung hyperinflation → increased intrathoracic pressure → reduced venous return → hemodynamic compromise. Detected by expiratory hold maneuver. Managed by: low RR (10–12/min), prolonged I:E (1:3 to 1:4), low set PEEP (3–5 cmH₂O), bronchodilators, suctioning.
When do antibiotics help in AECOPD and when don't they?
The Anthonisen 1987 landmark trial defined 3 cardinal symptoms: increased dyspnea, increased sputum volume, and increased sputum purulence. Antibiotics benefit patients with all 3 symptoms (NNT ~3–4) or those requiring NIV/intubation. Only 1 symptom present = no antibiotic benefit. Procalcitonin can help guide the decision -PCT < 0.1 suggests viral etiology, withhold antibiotics. PRORATA 2010
NIV vs intubation -when do you escalate?
NIV reduces intubation, mortality, and LOS in hypercapnic AECOPD with pH 7.25–7.35 Brochard 1995. Reassess at 1–2h. Intubate if: pH < 7.25 or worsening, PaCO₂ rising on NIV, RR still > 30, worsening consciousness/agitation, inability to clear secretions, hemodynamic instability. Don't wait too long -a crashing COPD patient is technically difficult to intubate (hyperinflation → hemodynamic instability on intubation).
Clinical Examples
📋 Case 1, Severe AECOPD Requiring NIV
Patient: 68M with GOLD 3 COPD (FEV1 35%), current smoker, presents with 3 days of worsening dyspnea, increased purulent sputum, and confusion. Uses tiotropium and PRN albuterol at home.
Key findings: RR 28, SpO2 82% on RA, HR 110, accessory muscle use, tripod position. ABG on 2L NC: pH 7.28, PaCO2 78, PaO2 55. CXR: hyperinflation, no infiltrate. Procalcitonin 0.08.
Management:
- Albuterol/ipratropium (DuoNeb) q20min x 3, then q4h. Target SpO2 88-92% Austin, 2010
- BiPAP: IPAP 12-14 / EPAP 5, titrate to comfort. Reassess ABG in 1-2h
- Prednisone 40 mg PO daily x 5 days (no taper needed) REDUCE, 2013
- Antibiotics: amoxicillin-clavulanate (Anthonisen Type 1 -- all 3 cardinal symptoms present)
Teaching point: NIV is the most important intervention in hypercapnic AECOPD (pH 7.25-7.35). The Haldane effect -- not suppression of hypoxic drive -- is the main reason over-oxygenation worsens CO2 retention.
📋 Case 2, Intubated COPD with Auto-PEEP
Patient: 72F with severe COPD, intubated for respiratory failure after failing NIV (pH 7.18, obtunded). 20 minutes post-intubation, BP drops to 70/40, HR rising to 130.
Key findings: Vent settings: AC 16/500/FiO2 60%/PEEP 5. Peak airway pressure 45 cmH2O. Expiratory flow waveform does not return to zero (air trapping). Expiratory hold: intrinsic PEEP 14 cmH2O. Bilateral breath sounds present (not pneumothorax).
Management:
- Immediate: disconnect ETT from vent for 30-60 seconds (passive exhalation). BP recovers = confirms auto-PEEP
- Adjust vent: decrease RR to 10-12, prolong I:E to 1:4, reduce tidal volume, set extrinsic PEEP to ~80% of measured auto-PEEP
- Aggressive bronchodilation: continuous albuterol via in-line nebulizer + IV magnesium 2g
- Deep sedation + paralysis if severe air trapping persists (eliminate patient-ventilator dyssynchrony)
Teaching point: Hypotension after intubation in COPD = auto-PEEP until proven otherwise. Disconnecting from the vent is both diagnostic and therapeutic. Three causes of post-intubation hypotension: auto-PEEP, tension pneumothorax, and sedation-induced vasodilation.
📋 Case 3, Mild AECOPD with Discharge Planning
Patient: 58F with moderate COPD (GOLD 2, FEV1 55%), presents with 4 days of increased dyspnea and change in sputum color. No accessory muscle use. Uses albuterol PRN only -- not on any maintenance inhaler.
Key findings: RR 20, SpO2 93% on RA, HR 88. Diffuse expiratory wheezing. ABG: pH 7.38, PaCO2 42. CXR: hyperinflation only. Procalcitonin 0.35.
Management:
- DuoNeb q4h, prednisone 40 mg PO daily x 5 days
- Doxycycline 100 mg BID x 5 days (Anthonisen Type 2 -- dyspnea + purulence)
- Observe 24h. If improving: discharge with prednisone, antibiotic, and albuterol MDI
- Critical discharge intervention: Start LABA/ICS maintenance inhaler. Refer for pulmonary rehab. Smoking cessation counseling and NRT
Teaching point: Every AECOPD admission is an opportunity to optimize maintenance therapy and address smoking cessation. Pulmonary rehabilitation is the single most effective non-pharmacologic intervention for reducing future exacerbations.
📋 Sample Presentation
"Mr. Davies is a 67-year-old ex-smoker with GOLD 3 COPD who presented with 3 days of worsening dyspnea, increased purulent sputum, and confusion. On arrival he was in moderate respiratory distress -RR 28, SpO₂ 82% on room air, using accessory muscles. ABG showed pH 7.28, PaCO₂ 78, PaO₂ 52 on 2L NC. CXR showed hyperinflation with no new infiltrate. He was started on albuterol/ipratropium (DuoNeb) nebs, prednisolone 40 mg, and amoxicillin-clavulanate. NIV was initiated -IPAP 14 / EPAP 5 -with SpO₂ target 88–92%. Repeat ABG at 2 hours showed pH 7.34, PaCO₂ 68 -improving on NIV. He is now more alert, RR 20, on NIV cycling with breaks for meals. Today's plan: continue NIV, wean to Venturi mask for meals, antibiotic day 2, maintain O₂ target 88–92%."
Rounds Checklist
- SpO₂ 88–92% confirmed? Not on high-flow O₂?
- Latest ABG -pH and PaCO₂ trend?
- NIV hours per day? Mask tolerance?
- Bronchodilator frequency -still q4h? Ready to wean to q6h?
- Steroid day #? (5-day course)
- Antibiotic day #? (5–7 days). Sputum cultures back?
- Potassium -check daily with frequent nebs
- Glucose -steroid hyperglycemia?
- Ambulation -physio ordered?
- Discharge planning -inhalers correct technique, follow-up, smoking cessation
Monitoring Protocol
| Parameter | Frequency | Target / Action |
|---|---|---|
| SpO₂ | Continuous | 88–92% in CO₂ retainers. NOT 94–98%. |
| ABG | At 30–60 min after O₂/NIV start, then q4–6h if on NIV | pH improving, PaCO₂ stable or falling |
| RR, accessory muscle use | q1–2h | RR decreasing; less accessory muscle use = good response |
| Mental status | q1–2h on NIV | Worsening confusion → intubate |
| Potassium | q4–6h if frequent nebs | Hypokalemia with frequent albuterol + steroids; replace aggressively |
| Glucose | q6h if on steroids | Steroid hyperglycemia -use insulin sliding scale |
| ECG | On admission + PRN | New AF common in AECOPD; rate control with diltiazem or digoxin (avoid BB) |
| CXR | On admission, repeat if worsening | Exclude new pneumonia, pneumothorax, effusion |
NIV Monitoring Checklist
- Check ABG 1–2h after starting NIV -if no improvement → escalate
- Mask fit -leaks significantly reduce effectiveness
- Patient tolerance -sedation is NOT used with NIV (risks aspiration)
- Titrate IPAP for TV 6–8 mL/kg and patient comfort
- SpO₂ 88–92% while on NIV
- Reassess every 2–4h -early identification of NIV failure critical
Ventilator Settings if Intubated
| Parameter | Setting | Rationale |
|---|---|---|
| Mode | AC/VC | Volume control preferred for predictable TV delivery |
| Tidal volume | 6–8 mL/kg PBW | Lower than ARDS -compliance better but still protect lungs |
| Rate | 10–12 /min (low!) | Low RR = more time to exhale = less auto-PEEP |
| I:E ratio | 1:3 to 1:4 | Prolonged expiratory time to reduce air trapping |
| PEEP | 3–5 cmH₂O (low) | Counter auto-PEEP partially; high PEEP worsens hyperinflation |
| FiO₂ | Titrate to SpO₂ 88–92% | Same target as non-intubated |
Post-Intubation Hypotension: Severe auto-PEEP → impaired venous return → hemodynamic collapse. Disconnect ETT, allow passive exhalation. Give IV fluid bolus. Reduce RR.
⚡ Summary
Summary
Define It, Then Exclude the 6 P's
Sustained worsening of dyspnea, cough or sputum beyond normal day-to-day variation, and it is a diagnosis of exclusion. The 6 P's are the alternative diagnoses: PE, Pneumonia, Pneumothorax, Pump failure, Pulse (ACS or arrhythmia), Plug or aspiration. Precipitants of a true exacerbation are separate: infection, pollution and irritants, and non-adherence. PE is the highest-yield miss, roughly 1 in 6 of unexplained exacerbations.
NIV Before Intubation
BiPAP in hypercapnic respiratory failure with pH below 7.35 reduces intubation, mortality and length of stay, and it is one of the strongest evidence bases in respiratory medicine. Start it early rather than after a trial of failure, and reassess with a blood gas within an hour: a pH that is not improving is NIV failure and means intubation.
Bronchodilators Plus Steroids Are the Backbone
Short-acting beta agonist with an anticholinergic, and systemic corticosteroids. Prednisone 40 mg daily for 5 days is sufficient (REDUCE showed 5 days non-inferior to 14), and oral is as effective as IV. Longer courses add hyperglycemia, infection and bone loss without benefit.
Target Oxygen at 88 to 92%
Not higher. Excess oxygen causes hypercapnia through V/Q mismatch from released hypoxic vasoconstriction and the Haldane effect, not simply by removing hypoxic drive, and it increases mortality in prehospital COPD care. Titrate deliberately rather than leaving a non-rebreather running.
Antibiotics for the Right Patients
Give them for two or more of increased dyspnea, increased sputum volume, and increased sputum purulence, or for any patient requiring ventilatory support. Purulence is the single most useful of the three. Typical agents cover H. influenzae, S. pneumoniae and M. catarrhalis; add Pseudomonas cover for frequent exacerbations, prior isolation, bronchiectasis or recent broad-spectrum exposure.
Do Not Spirometer Them Acutely
Spirometry during an exacerbation is inaccurate and does not guide management. Do it at follow-up once recovered, which is also when the maintenance regimen should be reviewed. The same applies to labeling severity by FEV1 during the admission.
Do Not Run the Asthma Protocol
Steroid dose and duration, antibiotic use and oxygen targets all differ. Asthma gets higher steroid doses without routine antibiotics and a normal oxygen target; COPD gets 5 days of prednisone, selective antibiotics and 88 to 92%. Mixing them over-treats one and under-treats the other.
Optimize Before Discharge, Because Readmission Is the Rule
Confirm inhaler technique, review and step up maintenance therapy, vaccinate, refer to pulmonary rehabilitation, and address smoking. Arrange follow-up within 1 to 4 weeks. Exacerbations cluster and each one accelerates lung function decline, so the discharge is the intervention point for the next one. Assess for long-term oxygen only after recovery, not on the acute gas.
📄 One Pager
Text version
Pulmonology · ICU · One Pager
AECOPD
Target O₂ 88–92%, NOT 94–98%. NIV before intubation. 5-day steroids. Antibiotics only if 2–3 Anthonisen criteria. Don't miss PE.
Anthonisen Criteria
① Increased dyspnea
② Increased sputum volume
③ Increased sputum purulence
2–3 present → give antibiotics Anthonisen 1987
1 present → no antibiotic benefit
② Increased sputum volume
③ Increased sputum purulence
2–3 present → give antibiotics Anthonisen 1987
1 present → no antibiotic benefit
ABG -Severity Guide
pH 7.35–7.45 + ↑PaCO₂Chronic compensated
pH < 7.35 + ↑PaCO₂Acute -start NIV
pH < 7.25Severe -low threshold intubate
pH < 7.15Intubate -NIV failing
Management -Step by Step
1
O₂ target 88–92% -start 1–2L NC, titrate up. Check ABG at 30–60 min. Austin 2010
2
Bronchodilators: Albuterol (Ventolin) 2.5–5 mg + ipratropium (Atrovent) 0.5 mg neb q20 min × 3 → q4–6h, or DuoNeb
3
Steroids: Prednisolone 40 mg PO × 5 days REDUCE, 2013
4
Antibiotics if ≥ 2 Anthonisen criteria: Amox-clav 875/125 mg BID or doxycycline × 5–7d
5
NIV (BiPAP) if pH < 7.35 + PaCO₂ > 45 -IPAP 12–16, EPAP 4–5. Check ABG at 1–2h. Brochard 1995
6
Intubate if NIV fails (pH worsening, AMS, RR still > 30). Low RR (10–12), I:E 1:3, low PEEP.
Key Drugs
Albuterol (Ventolin)2.5–5 mg neb q20 min
Ipratropium0.5 mg neb q20 min
Prednisolone40 mg PO × 5d
Amox-clav875/125 mg PO BID × 5–7d
Monitoring
- SpO₂ 88–92% target
- ABG at 1–2h after NIV start
- K⁺ daily (albuterol + steroids)
- Glucose q6h (steroids)
- ECG -new AF common
Pitfalls
- High-flow O₂ → CO₂ retention
- Steroids > 5 days (not needed)
- Antibiotics for viral AECOPD
- Missing PE, the highest-yield alternative diagnosis
- High PEEP in auto-PEEP patient
- High RR on vent → air trapping
NIV Success Criteria (check at 1–2h)
- pH improving toward 7.35
- PaCO₂ stable or falling
- RR decreasing
- More alert and cooperative
- Accessory muscle use decreasing
Key Trials
- Brochard 1995: NIV reduces intubation + mortality
- REDUCE 2013: 5d steroids = 14d
- Anthonisen 1987: Antibiotic criteria
- Austin 2010: Titrated O₂ reduces mortality 58%
- UPLIFT 2008: Tiotropium reduces exacerbations
Related Topics
Acute Decompensated Heart FailureAcute Ischemic StrokeAcute Mesenteric IschemiaAcute PancreatitisAirway & Ventilator ManagementAlcohol Withdrawal & DTs